241 related articles for article (PubMed ID: 10637363)
1. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
Singh SM; Gauthier S; Labrie F
Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
[TBL] [Abstract][Full Text] [Related]
2. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
4. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor.
Teutsch G; Goubet F; Battmann T; Bonfils A; Bouchoux F; Cerede E; Gofflo D; Gaillard-Kelly M; Philibert D
J Steroid Biochem Mol Biol; 1994 Jan; 48(1):111-9. PubMed ID: 8136296
[TBL] [Abstract][Full Text] [Related]
5. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
7. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
Ayub M; Levell MJ
J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
[TBL] [Abstract][Full Text] [Related]
8. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
[TBL] [Abstract][Full Text] [Related]
10. Identification of steroid derivatives that function as potent antiandrogens.
Miyamoto H; Marwah P; Marwah A; Yang Z; Chung CY; Altuwaijri S; Chang C; Lardy H
Int J Cancer; 2005 Dec; 117(5):866-72. PubMed ID: 15981214
[TBL] [Abstract][Full Text] [Related]
11. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
13. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
Nguyen TV; Yao M; Pike CJ
Endocrinology; 2007 Jun; 148(6):2936-43. PubMed ID: 17347309
[TBL] [Abstract][Full Text] [Related]
14. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
Gaillard-Moguilewsky M
Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
